| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5f13fef9231e077e9b4a6637a6dc90d2 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C51-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C67-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C57-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C53-126 |
| filingDate |
1987-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e881d6ce694aeef77f0db10380595aab
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89798695a7d2fed07f95f2f970fdcaa7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8a88bd17203f1d960f121fb0260184fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ce9b725ef1898cfb13f0220e8adab6ac |
| publicationDate |
1988-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-0257081-A1 |
| titleOfInvention |
Method of modifying the lipid structure of cell membranes and pharmaceutical compositions for use therein |
| abstract |
Use of certain fatty acids to produce changes in the lipid structure of cell membranes. The invention also relates to the formulation of pharmaceutical compositions and medicaments and to its products per se; to the treatment of a set of clinical and veterinary disorders associated with the elevation of the saturation index of cell membranes, in particular of nervous disorders including multiple sclerosis and schizophrenia; as well as the use of active substances which are the subject of the invention in the treatment of said disorders. The active ingredients described are monounsaturated fatty acids having from 12 to 28 carbon atoms in the alkyl chain, for example oleic acid, or pharmaceutically acceptable derivatives. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11305513-B2 |
| priorityDate |
1986-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |